

Financial Tearsheet

Company Overview

Neuropathix, Inc. is a biopharmaceutical medchem company focused on the research and development of a pipeline of patented socially responsible pain management therapeutics to treat patients with significant unmet medical needs. The Company's family of proprietary molecules focuses on treating oxidative stress-related diseases, chronic pain management and neurodegenerative disorders. The therapeutic targets include chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports. Neuropathix conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

Recent Financial News

Date	Headline
Jan 25, 2021	Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead
Jan 19, 2021	Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant
Jan 12, 2021	Neuropathix, Inc. Appoints World-Renowned Pain Management Clinician Dr. Daniel Richman to the Company's Scientific Advisory Board
Dec 21, 2020	Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate
Nov 19, 2020	Neuropathix, Inc. Signs Binding Letter of Intent to Acquire Anticonvulsant - Neuroprotective Intellectual Property
















IR Contacts

Investor Relations Investor Relations Firm CORE IR 377 Oak Street Garden City, NY 11530 (516) 222-2285 www.coreir.com Contact: John Marco Johnm@coreir.com	Transfer Agent Securities Transfer Corp. 2901 Dallas Parkway, Suite 380, Plano, TX 75093 (469) 633-0101 www.stctransfer.com
Auditors DBB McKennon 12790 El Camino Real #130 San Diego, CA 92130 (858) 217-4035 www.dbbmckennon.com	Corporate Counsel Procopio, Cory, Hargreaves & Savitch LLP. 525 B Street, Suite 2200 San Diego, CA 92101 (619) 238-1900 www.procopio.com

Stock Performance

Today's Open	0.2001
Volume	143,144
Day Range	0.2000 - 0.2087
52 Week Range	0.1300 - 1.5000
Bid/Ask	0.0000 / 0.0000
Bid/Ask Size	0 X 0
Previous Close	0.2000
Market Cap	15.05 million
Shares Outstanding	75.25 million
Dividend/Yield	0.0000 / 0.0000%
EPS (TTM)	-0.050000
P/E Ratio (TTM)	N/A

Recent XBRL Filings

Filing Date ▾	Form Type	Description	View
Nov 12, 2020	10-Q	Quarterly report	  
Aug 12, 2020	10-Q	Quarterly report	  
May 14, 2020	10-Q	Quarterly report	  
Mar 30, 2020	10-K	Annual report	  
Nov 13, 2019	10-Q	Quarterly report	  

Management Team

Dean Petkanas, Chairman & CEO

William A. Kinney, PHD, Chief Scientific Officer

Thoma Kikis, Chief Communications Officer, Board Director

Mark Corrao, Chief Financial Officer

Board of Directors

Dean Petkanas, Chairman & CEO

Thoma Kikis, Founder / Chief Communications Officer, Board Director

Robert Malasek, Director

Blake Schroeder, Director

Timothy Scott, PhD, Director